Found 8 results. Export: Tagged | XML
Filters: author is Tuk  [Clear All Filters]
2002
Tuk, B., van Gool, T., Danhof, M. , Mechanism-based pharmacodynamic modeling of the interaction of midazolam, bretazenil, and zolpidem with ethanol, J Pharmacokinet Pharmacodyn, vol. 29, no. 3, pp. 235-50.
2000
Karlsson, M.O., Schoemaker, R.C., Kemp, B., Cohen, A.F., van Gerven, J.M., Tuk, B., Peck, C.C., Danhof, M. , A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep, Clin Pharmacol Ther, vol. 68, no. 2, pp. 175-88. DOI
1999
Tuk, B., van Oostenbruggen, M.F., Herben, V.M., Mandema, J.W., Danhof, M. , Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam, J Pharmacol Exp Ther, vol. 289, no. 2, pp. 1067-74.
1998
Tuk, B., Herben, V.M., Mandema, J.W., Danhof, M. , Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam, J Pharmacol Exp Ther, vol. 284, no. 1, pp. 202-7.
1997
Tuk, B., Oberye, J.J., Pieters, M.S., Schoemaker, R.C., Kemp, B., van Gerven, J., Danhof, M., Kamphuisen, H.A., Cohen, A.F., Breimer, D.D., Peck, C.C. , Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement of sleep, Clin Pharmacol Ther, vol. 62, no. 4, pp. 444-52. DOI
Tuk, B., Danhof, M., Mandema, J.W. , The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates, J Pharmacokinet Biopharm, vol. 25, no. 1, pp. 39-62.
1993
Van Steveninck, A.L., Mandema, J.W., Tuk, B., Van Dijk, J.G., Schoemaker, H.C., Danhof, M., Cohen, A.F. , A comparison of the concentration-effect relationships of midazolam for EEG-derived parameters and saccadic peak velocity, Br J Clin Pharmacol, vol. 36, no. 2, pp. 109-15.
1992
Mandema, J.W., Tuk, B., van Steveninck, A.L., Breimer, D.D., Cohen, A.F., Danhof, M. , Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers, Clin Pharmacol Ther, vol. 51, no. 6, pp. 715-28.